P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Asthma Treatments and What Matters to Patients

P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Vogelberg C, Szefler S, Hamelmann E, et al

P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma

Thorax 2016;71:A167.